DK0972020T3 - Agonistmolekyler rettet imod insulinlignende vækstfaktorer - Google Patents

Agonistmolekyler rettet imod insulinlignende vækstfaktorer

Info

Publication number
DK0972020T3
DK0972020T3 DK98915236T DK98915236T DK0972020T3 DK 0972020 T3 DK0972020 T3 DK 0972020T3 DK 98915236 T DK98915236 T DK 98915236T DK 98915236 T DK98915236 T DK 98915236T DK 0972020 T3 DK0972020 T3 DK 0972020T3
Authority
DK
Denmark
Prior art keywords
growth factors
directed against
agonist molecules
molecules directed
against insulin
Prior art date
Application number
DK98915236T
Other languages
English (en)
Inventor
Ross G Clark
Henry B Lowman
Iain C A F Robinson
Original Assignee
Genentech Inc
Iain C A F Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Iain C A F Robinson filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0972020T3 publication Critical patent/DK0972020T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK98915236T 1997-04-04 1998-03-31 Agonistmolekyler rettet imod insulinlignende vækstfaktorer DK0972020T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/825,852 US6121416A (en) 1997-04-04 1997-04-04 Insulin-like growth factor agonist molecules
PCT/US1998/006514 WO1998045427A2 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist peptides

Publications (1)

Publication Number Publication Date
DK0972020T3 true DK0972020T3 (da) 2003-02-03

Family

ID=25245064

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98915236T DK0972020T3 (da) 1997-04-04 1998-03-31 Agonistmolekyler rettet imod insulinlignende vækstfaktorer

Country Status (13)

Country Link
US (16) US6121416A (da)
EP (2) EP1251137A3 (da)
JP (1) JP4562814B2 (da)
AT (1) ATE224951T1 (da)
AU (1) AU732989B2 (da)
CA (1) CA2286264A1 (da)
DE (1) DE69808258T2 (da)
DK (1) DK0972020T3 (da)
ES (1) ES2183344T3 (da)
HK (1) HK1047755A1 (da)
IL (1) IL131925A0 (da)
PT (1) PT972020E (da)
WO (1) WO1998045427A2 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
US20030224017A1 (en) * 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
DE60027042D1 (de) * 1999-10-29 2006-05-18 Univ Oregon Health Sciences Modulation der neurokrinen differenzierung durch protein 25.1
US6689747B2 (en) 2000-03-24 2004-02-10 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
FR2810675B1 (fr) * 2000-06-22 2002-09-27 Pf Medicament Construction modifiee en aval du codon d'initiation pour la surexpression de proteines recombinantes
WO2002043578A2 (en) * 2000-11-28 2002-06-06 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6790672B2 (en) * 2001-02-19 2004-09-14 Board Of Regents The University Of Texas System Encoded molecular sieve particle-based sensors
US7071300B2 (en) 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
AU2002363800A1 (en) * 2001-11-13 2003-05-26 Loi Tran Therapeutic agent composition and method of use
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
US7118877B2 (en) * 2002-07-08 2006-10-10 Wyeth Caspase 9 activation and uses therefor
EP1534314B1 (en) * 2002-09-04 2014-10-22 DSM IP Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
EP1540815B1 (en) * 2002-09-06 2006-12-27 Telefonaktiebolaget LM Ericsson (publ) Composite power amplifier
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
MXPA05005022A (es) * 2002-11-14 2005-08-03 Wyeth Corp Metodos y composiciones para tratar trastornos neurologicos.
US7273788B2 (en) * 2003-05-21 2007-09-25 Micron Technology, Inc. Ultra-thin semiconductors bonded on glass substrates
ES2323425T3 (es) * 2003-06-06 2009-07-15 Genentech, Inc. Modulacion de la interaccion entre la cadena beta de hgf y c-met.
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
ES2541673T3 (es) 2003-09-12 2015-07-23 Ipsen Biopharmaceuticals, Inc. Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (IGF-1)
WO2005033132A2 (en) * 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP2336178A1 (en) 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
BRPI0508670B1 (pt) * 2004-03-19 2023-01-24 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas, usos das referidas citotoxinas para o tratamento de câncer, composição farmacêutica, processo de preparação de produto farmacêutico, ácidos nucléicos e peptídeos de epítopo de célula t
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CA2589885A1 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
EP2190433A2 (en) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
CA2715628A1 (en) 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
CA2812785A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
US8623821B2 (en) 2011-10-14 2014-01-07 Genentech, Inc. Zymogen activators
EP2766028B1 (en) 2011-10-14 2017-08-16 F. Hoffmann-La Roche AG Peptide inhibitors of bace1
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
MX2020002744A (es) 2017-09-11 2020-10-01 Takeda Pharmaceuticals Co Metodos y composiciones para tratar enfermedades pulmonares cronicas.
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING MILD COGNITIVE DISORDER, DEPRESSION AND PSYCHOLOGICAL DISORDERS
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
GB201913196D0 (en) 2019-09-12 2019-10-30 Univ Newcastle Culture method
AU2021364523A1 (en) 2020-10-19 2023-04-06 Oak Hill Bio Limited Compositions suitable for use in neonates
DE102021122096A1 (de) 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
CN117347626B (zh) * 2023-12-06 2024-03-12 安徽惠邦生物工程有限公司 人胰岛素样生长因子结合蛋白-1化学发光免疫分析试剂盒及其制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
PH23185A (en) 1983-06-13 1989-05-29 Scheindel Ass Inc Pressure operated dispensing container
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
EP0134094B1 (en) 1983-08-15 1987-05-27 AMP INCORPORATED (a New Jersey corporation) An improved compliant section for circuit board contact elements
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
JP2648951B2 (ja) * 1987-04-06 1997-09-03 セルトリックス ファーマシュウティカルズ，インク 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
ES2007309T3 (es) * 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5164370A (en) * 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
ATE86496T1 (de) * 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) * 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) * 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP0575485A1 (en) * 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
WO1993002695A1 (en) * 1991-08-01 1993-02-18 Genentech, Inc. Igf-1 to improve the neural condition
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1993025219A1 (en) * 1992-06-12 1993-12-23 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
EP0686040A1 (en) * 1993-01-29 1995-12-13 Amgen Boulder Inc. Wound healing composition
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
HU221092B1 (en) * 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
HU224345B1 (hu) * 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
EP0828758B1 (en) * 1995-05-26 2001-08-29 Theratechnologies Inc. Chimeric fatty body-pro-grf analogs with increased biological potency
JP4050314B2 (ja) * 1995-06-07 2008-02-20 オーソ ファーマシューティカル コーポレイション エリトロポエチン受容体に結合する化合物およびペプチド
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
PE7898A1 (es) * 1995-06-07 1998-03-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
AU2676297A (en) * 1996-04-17 1997-11-07 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
DE59705394D1 (de) 1996-04-25 2001-12-20 Storz Karl Gmbh & Co Kg Chirurgisches instrumentensystem
US6428781B1 (en) 1996-12-27 2002-08-06 Daiichi Pharmaceutical Co., Ltd. Composition of an endogenous insulin-like growth factor-II derivative
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Also Published As

Publication number Publication date
US6251865B1 (en) 2001-06-26
CA2286264A1 (en) 1998-10-15
US6620789B1 (en) 2003-09-16
DE69808258T2 (de) 2003-09-18
EP1251137A3 (en) 2003-04-16
WO1998045427A3 (en) 1999-01-07
ES2183344T3 (es) 2003-03-16
PT972020E (pt) 2003-02-28
AU6947098A (en) 1998-10-30
US6635619B1 (en) 2003-10-21
DE69808258D1 (de) 2002-10-31
IL131925A0 (en) 2001-03-19
ATE224951T1 (de) 2002-10-15
JP2002510194A (ja) 2002-04-02
US6121416A (en) 2000-09-19
US6632794B1 (en) 2003-10-14
AU732989B2 (en) 2001-05-03
EP0972020A1 (en) 2000-01-19
EP1251137A2 (en) 2002-10-23
US6693079B1 (en) 2004-02-17
EP0972020B1 (en) 2002-09-25
US6689751B1 (en) 2004-02-10
US6608031B1 (en) 2003-08-19
US6683053B1 (en) 2004-01-27
US6716586B1 (en) 2004-04-06
WO1998045427A2 (en) 1998-10-15
HK1047755A1 (zh) 2003-03-07
US6680298B1 (en) 2004-01-20
US6693078B1 (en) 2004-02-17
JP4562814B2 (ja) 2010-10-13
US6949349B1 (en) 2005-09-27
US6645775B1 (en) 2003-11-11
US6677305B1 (en) 2004-01-13
US6713451B1 (en) 2004-03-30

Similar Documents

Publication Publication Date Title
DK0972020T3 (da) Agonistmolekyler rettet imod insulinlignende vækstfaktorer
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
BR9810651A (pt) Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos
EE9900345A (et) Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks
BR9811948A (pt) Secretores de hormÈnio do crescimento
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
DE69810171D1 (de) Verwendung von 1,4-Naphthochinon- und 1,4-dihydroxynaphthalin-Pyrrolderivaten zum Färben von Keratinsubstanzen, Verbindungen und diese enthaltende Zusammensetzungen
DE69838730D1 (de) Zusammensetzung zur zahnbeschichtung
DK1282437T3 (da) Behandling af brusklidelser
FI954805A0 (fi) Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
WO2000002916A3 (en) PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY
NL1009876A1 (nl) Synergistisch stabilisatormengsel op basis van polyalkyl-1-oxa-diazaspirodecaanverbindingen.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
ATE321589T1 (de) Verwendung einer zubereitung und ein kosmetisches verfahren zur verminderung und vorbeugung von beissender der haut
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
EP1073623A4 (en) AMINO ACIDS SUBSTITUTED AS ERYTHROPOIETINE IMITATION
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
ES2083636T3 (es) Componente adhesivo para la restauracion de la sustancia dental dura.
ATE180679T1 (de) Neue verbesserungen hinsichtlich der radiomarkierung von proteinen
ES2147519B1 (es) Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
DE60027301D1 (de) Zweikomponentenzusammensetzungen zur kosmetischen oder pharmazeutischen verwendung